Author:
Cartwright Thomas H.,Parisi Monika,Espirito Janet L.,Wilson Thomas W.,Pelletier Corey,Patel Manish,Babiker Hani M.
Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
2. Surveillance, Epidemiology, and End Results Program. SEER stat facts: pancreas cancer.
http://www.seer.cancer.gov
. Accessed 9 Aug 2017.
3. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patient with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403–13.
4. NCCN. Clinical practice guidelines in oncology: pancreatic adenocarcinoma. Version 2. 2015.
http://www.nccn.org
. Accessed 3 Feb 2016.
5. Von Hoff DD, Ervin TJ, Arena FP, et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT) [abstract]. J Clin Oncol. 2013;31(Suppl. 4):LBA148.
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献